ERBB2 and breast cancer: By inhibiting HER2 heterodimerization, pertuzumab acts synergistically with other HER2-targeted therapies, such as trastuzumab, to provide a complete blockade of HER2 signaling and improve treatment outcomes for patients with HER2+ breast cancer.